• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Artificial kidneys and clearance calculations.

作者信息

Gibson T P, Matusik E, Nelson L D, Briggs W A

出版信息

Clin Pharmacol Ther. 1976 Dec;20(6):720-6. doi: 10.1002/cpt1976206720.

DOI:10.1002/cpt1976206720
PMID:991541
Abstract

Clearance of solutes by artificial kidneys can be calculated using plasma flow and solute concentration, whole blood flow and plasma solute concentration, and midpoint of dialysis blood or plasma solute concentration and total amount of solute removed. Using these methods, the clearance of procainamide (PA) and N-acetylprocainamide (NAPA) was determined in 4 patients. In all but one case clearances using total amount recovered were greater than clearances using whole blood flow and plasma concentration. Without exception, clearance determined using amount recovered was substantially greater than clearance using plasma flow and plasma levels, suggesting that both PA and NAPA are removed not only from plasma but also from red blood cells. In vitro clearance of PA, NAPA, quinidine, and phenobarbital by 11 clinically available artificial kidneys and an XAD-4 hemoperfusion column was determined and differences were found.

摘要

相似文献

1
Artificial kidneys and clearance calculations.
Clin Pharmacol Ther. 1976 Dec;20(6):720-6. doi: 10.1002/cpt1976206720.
2
Procainamide and N-acetylprocainamide kinetics investigated simultaneously with stable isotope methodology.采用稳定同位素方法同时研究普鲁卡因胺和N-乙酰普鲁卡因胺的动力学。
Clin Pharmacol Ther. 1977 Oct;22(4):447-57. doi: 10.1002/cpt1977224447.
3
N-Acetylprocainamide levels in patients with end-stage renal failure.终末期肾衰竭患者的N-乙酰普鲁卡因胺水平
Clin Pharmacol Ther. 1976 Feb;19(2):206-12. doi: 10.1002/cpt1976192206.
4
Disposition of procainamide and N-acetylprocainamide in protein-calorie malnutrition.蛋白质 - 热量营养不良时普鲁卡因胺和N - 乙酰普鲁卡因胺的处置
Drug Metab Dispos. 1985 May-Jun;13(3):359-63.
5
Pharmacokinetics of N-acetylprocainamide in patients profiled with a stable isotope method.用稳定同位素法分析的患者中N-乙酰普鲁卡因胺的药代动力学
Clin Pharmacol Ther. 1989 Aug;46(2):182-9. doi: 10.1038/clpt.1989.124.
6
Kinetics of procainamide and N-acetylprocainamide in renal failure.肾衰竭患者中普鲁卡因胺和N - 乙酰普鲁卡因胺的动力学
Kidney Int. 1977 Dec;12(6):422-9. doi: 10.1038/ki.1977.133.
7
Cumulation of N-acetylprocainamide, an active metabolite of procainamide, in patients with impaired renal function.肾功能受损患者体内普鲁卡因酰胺的活性代谢产物N-乙酰普鲁卡因酰胺的蓄积。
Clin Pharmacol Ther. 1977 Jul;22(1):63-9. doi: 10.1002/cpt197722163.
8
N-Acetylprocainamide pharmacokinetics in functionally anephric patients before and after perturbation by hemodialysis.无尿患者在血液透析干扰前后的N-乙酰普鲁卡因胺药代动力学
Clin Pharmacol Ther. 1979 Nov;26(5):618-28. doi: 10.1002/cpt1979265618.
9
Procainamide pharmacokinetics in beagles: urinary pH dependency and comparison with n-acetylprocainamide.
Res Commun Chem Pathol Pharmacol. 1977 Jun;17(2):333-6.
10
Dose and concentration dependent effect of ranitidine on procainamide disposition and renal clearance in man.雷尼替丁对人体内普鲁卡因胺处置和肾清除率的剂量及浓度依赖性效应。
Br J Clin Pharmacol. 1984 Aug;18(2):175-81. doi: 10.1111/j.1365-2125.1984.tb02450.x.

引用本文的文献

1
Pharmacokinetics and haemodynamics of candesartan cilexetil in hypertensive patients on regular haemodialysis.坎地沙坦酯在规律血液透析高血压患者中的药代动力学和血流动力学
Br J Clin Pharmacol. 1999 Jun;47(6):645-51. doi: 10.1046/j.1365-2125.1999.00939.x.
2
Pharmacokinetics of fleroxacin after multiple oral dosing in patients receiving regular hemodialysis.接受定期血液透析患者多次口服氟罗沙星后的药代动力学
Antimicrob Agents Chemother. 1996 Aug;40(8):1903-9. doi: 10.1128/AAC.40.8.1903.
3
The effect of haemodialysis on the pharmacokinetics of perindoprilat after long-term perindopril.
长期服用培哚普利后血液透析对培哚普利拉药代动力学的影响。
Eur J Clin Pharmacol. 1993;44(2):183-7. doi: 10.1007/BF00315478.
4
Drug dosage in end-stage renal disease (ESRD) patients undergoing haemodialysis. A predictive study based on a microcomputer program.接受血液透析的终末期肾病(ESRD)患者的药物剂量。一项基于微机程序的预测研究。
Clin Pharmacokinet. 1993 Sep;25(3):243-57. doi: 10.2165/00003088-199325030-00007.
5
Pharmacokinetics of acebutolol in patients with all grades of renal failure.醋丁洛尔在各程度肾衰竭患者中的药代动力学
Eur J Clin Pharmacol. 1980 May;17(5):339-48. doi: 10.1007/BF00558446.
6
Clearance calculations in hemodialysis: application to blood, plasma, and dialysate measurements for ethambutol.血液透析中的清除率计算:应用于乙胺丁醇的血液、血浆和透析液测量
J Pharmacokinet Biopharm. 1980 Feb;8(1):69-81. doi: 10.1007/BF01059449.
7
Pharmacokinetics of atenolol in patients with terminal renal failure and influence of haemodialysis.阿替洛尔在终末期肾衰竭患者中的药代动力学及血液透析的影响。
Br J Clin Pharmacol. 1980 Apr;9(4):379-85. doi: 10.1111/j.1365-2125.1980.tb01065.x.
8
Sorption kinetics in haemoperfusion columns. Part 2: modelling column performance.血液灌流柱中的吸附动力学。第2部分:柱性能建模。
Med Biol Eng Comput. 1981 Sep;19(5):627-37. doi: 10.1007/BF02442778.
9
Analysis of the contributions of permeability and flow of intercompartmental clearance.分析隔室间清除率的通透性和流量的贡献。
J Pharmacokinet Biopharm. 1981 Apr;9(2):167-80. doi: 10.1007/BF01068080.
10
Pharmacokinetics of sulfamethoxazole--trimethoprim combination during chronic peritoneal dialysis: effect of peritonitis.慢性腹膜透析期间复方磺胺甲恶唑的药代动力学:腹膜炎的影响
Eur J Clin Pharmacol. 1982;21(5):409-15. doi: 10.1007/BF00542328.